J.Safra Asset Management Corp Cytokinetics Inc Transaction History
J.Safra Asset Management Corp
- $991 Million
- Q2 2024
A detailed history of J.Safra Asset Management Corp transactions in Cytokinetics Inc stock. As of the latest transaction made, J.Safra Asset Management Corp holds 527 shares of CYTK stock, worth $27,309. This represents 0.0% of its overall portfolio holdings.
Number of Shares
527
Previous 71
642.25%
Holding current value
$27,309
Previous $4,000
600.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CYTK
# of Institutions
408Shares Held
126MCall Options Held
3.29MPut Options Held
2.01M-
Black Rock Inc. New York, NY14.7MShares$760 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$593 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.14MShares$422 Million0.28% of portfolio
-
Wellington Management Group LLP Boston, MA7.51MShares$389 Million0.07% of portfolio
-
State Street Corp Boston, MA6.55MShares$339 Million0.02% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.88B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...